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Background/Objectives: Successful engagement with and retention in medication treatment for 
opioid use disorder (MOUD) is an important focus in the fight against the opioid crisis. Gaps in 
opioid use disorder (OUD) care point to a need for improved understanding of factors that affect 
MOUD outcomes and how barriers may act as syndemic factors, compounding one another’s 
effects. This study used qualitative methods to solicit feedback about barriers to retention and 
successful treatment outcomes in methadone maintenance treatment (MMT) and used these 
findings to build a conceptual framework of interaction. 
Methods: This study was conducted at a community-based drug treatment center that serves a 
low-income population, the majority of whom identify as Black or African American. We 
recruited patients and staff as well as peer recovery coaches who work in OUD recovery across 
Baltimore City. Semi-structured interviews and focus groups asked about factors that influence 
MMT treatment outcomes and how barriers co-occur and interact. We used thematic analysis to 
examine themes pertaining to our research questions and two independent coders coded each 
transcript based on identified themes. 
Results: Patient participants (n=20) had a mean age of 48.4 (SD=10.0), 70% male, and 60% 
Black or African American. Mean reported age of first drug use was 17.7 (SD=5.1). Staff and 
peer recovery coach (PRC) participants (n=12) had a mean age of 49.2 (SD= 0.7), were 42% 
male, 75% Black or African American, with an average of 9.6 years working in substance use 
(SU) treatment. Barriers described by participants fit into several broad themes: individual/self, 
social, institutional or structural, community or environmental, and stigma. Participants 
described co-occurrence of these barriers as fueling one another and having a disastrous effect on 
treatment outcomes.  
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Conclusions: Understanding barriers to successful MOUD (specifically MMT) outcomes 
experienced by this vulnerable population and considering the synergistic effect of these barriers 
may assist with identification and promotion of the types of interventions needed to effectively 
and efficiently mitigate their impact. The conceptual model developed in the analysis of 
qualitative results for this study can inform future research, including quantitative analysis to 
build further support for the syndemic relationships presented in the model. 
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Psychosocial Syndemics Affecting Treatment Outcomes for  
Individuals Receiving Medication for Opioid Use Disorder 
The rate of opioid overdose deaths per year in the United States more than doubled 
between 2010 and 2017 and, in 2018, about 47,000 people died as a result of opioid overdose 
(Centers for Disease Control and Prevention (CDC), 2020). Such staggering statistics and 
tremendous loss of life contributed to the declaration of a national public health emergency in 
2017 and increased federal allocation of funds for treatment and recovery services for opioid use 
disorder (OUD) (US Department of Health & Human Services, 2017).  
The State of Maryland, and Baltimore City in particular, sits at the center of the US 
national overdose crisis. Maryland ranks within the top five states for age-adjusted opioid-related 
fatalities (Kaiser Family Foundation, 2020) and Baltimore City reported a drug overdose fatality 
rate in 2017 (45.1 per 100,000) that is higher than any other metropolitan county in the 
country(Baltimore City Health Department, 2018). In 2017, Governor Larry Hogan of Maryland 
declared a state of emergency in response to opioid-related fatalities (Exec. Order No. 
01.01.2017.02, 2017) and, in January 2019, he announced an executive order to study mental and 
behavioral health as related to substance use disorders (Exec. Order No. 01.01.2019.02, 2019). 
As the State focuses attention on overdose prevention and access to treatment, understanding the 
larger picture of determinants of successful treatment for OUD will allow for development of 
tailored services and modifications of existing programs to address gaps.  
Despite the relatively recent federal and state public recognition of the “opioid crisis,” 
some effective treatment strategies for OUD are well established, dating back to development in 
the 1960s (Joseph et al., 2000). Medication for OUD (MOUD) includes evidence-based 
approaches that incorporate prescribed medications (e.g. methadone, buprenorphine, and 
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naltrexone) and behavioral therapy (National Academies of Sciences, Engineering, and 
Medicine, 2018). Given the chronic course of OUD, long-term adherence to a regimen and 
retention in care is crucial to prevent withdrawal symptoms that can precipitate relapse and fatal 
overdoses. This study investigated psychosocial factors that may impact outcomes of MOUD, 
specifically methadone maintenance treatment (MMT) and how interaction between these factors 
can further contribute to poor treatment outcomes.  
MMT (like other MOUD options) is employed to relieve withdrawal symptoms and curb 
cravings by providing a safe and controlled level of medication. Like most current MOUD 
regimens, MMT involves daily dosing, but is unique in that it usually requires daily observed 
dosing (i.e., daily medication dispensed at the clinic and taken by patients in front of clinic staff). 
The necessary length of time on MMT varies on an individual basis, but prior research indicates 
that three months on treatment is needed to reduce or stop use, and optimal outcomes (long-term 
prevention of relapse) occur with longer durations of treatment (NIH, 2018). However, fewer 
than half of the people who initiate MMT are retained in treatment for at least twelve months 
(Reisinger et al., 2009). People who drop out of MMT experience 3.2 times the rate of all-cause 
mortality and 4.8 times the rate of overdose mortality compared to people who remain on 
treatment (Sordo et al., 2017). Thus, there is a serious public health need to identify and evaluate 
strategies that address barriers to MMT retention.  
The factors that interfere with MMT retention cannot be considered in isolation, but 
rather in the context of other disorders, social factors, and environmental exposures. Patients 
engaged in MMT frequently live with co-occurring psychosocial problems and stressors. For 
example, a random sample of women receiving MMT at methadone treatment clinics in New 
York City included 89.8% report of lifetime intimate partner violence, 37.8% report of childhood 
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physical abuse, and 28.1% PTSD diagnosis (Engstrom et al., 2012). Other findings from 
Baltimore, Maryland indicate almost 50% of patients newly admitted to an MMT program met 
diagnostic criteria for psychiatric disorders (Kidorf, 2018). Psychiatric comorbidity, 
homelessness, and violent victimization have all been shown to be associated with worse 
treatment outcomes for people receiving MMT or other treatment for substance use disorders 
(SUD) (Carpentier et al., 2009; Lo et al., 2018). However, there is little information available on 
the effect of co-occurrence of such barriers. A comprehensive investigation of the interaction 
between psychosocial and structural factors affecting MMT outcomes has not yet been 
conducted.  
  Syndemics theory is a conceptual model that may be particularly relevant to 
understanding the interactive effects of these psychosocial and contextual factors on MMT 
retention. “Syndemics” or “synergistic epidemics,” highlight the interaction between co-
occurring illness and other factors that compound the negative effect of one another (Singer, 
2009). The syndemics conceptual framework was originally developed in the setting of the early 
AIDS epidemic and is still commonly employed to understand factors that influence health 
disparities among people living with HIV (Singer, 1996; Wilson et al., 2014), including HIV 
transmission risk (Stall et al., 2003) and antiretroviral (ART) adherence (Blashill et al., 2015; 
Harkness et al., 2018). Although recent work has begun to consider how opioid use may overlap 
with other epidemics, for instance with HIV, HCV, and suicide (Fornili, 2018; Perlman & 
Jordan, 2018), to date, research has yet to elucidate the psychosocial and structural syndemic 
factors that influence important OUD treatment outcomes, such as MMT retention. Building off 
of prior work that applied the syndemics model to understanding psychosocial influences on 
ART adherence among people living with HIV, this study aimed to apply the syndemics 
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framework to consider psychosocial and contextual influences on MMT outcomes and establish 
a conceptual model on which to build future research.  
Therefore, this study employed a qualitative design to better understand syndemic factors 
that influence MMT outcomes in a community-based opioid treatment program in Baltimore 
City. Qualitative data, obtained through focus groups and individual interviews, helped identify 
factors affecting patient-defined MMT outcomes and provided insight into how those factors 
may co-occur and interact.  
Methods 
Setting 
This study took place at the University of Maryland Drug Treatment Center (UMDTC), a 
community-based, outpatient substance use treatment center in West Baltimore that has been 
providing substance use services to individuals living with opioid use disorder since 1972. The 
program is certified by the Maryland Department of Health and Commission on Accreditation of 
Rehabilitation Facilities (CARF). Currently, over three hundred patients receive MMT at this 
clinical site each day. MMT is dispensed daily Monday through Saturday at UMDTC, with a 
take-home dose given for Sunday. Patients start with an initiation dose (25 or 30 mg) that is 
increased/titrated by 5mg every other day until patients reach a “blocking dose” at which 
cravings are curbed (usually around 60 mg per day). After reaching a blocking dose, usually 
around two weeks after initiation, treatment plans are reviewed every 90 days, with input from 
the patient, their primary treatment counselor, and other treatment team members. With 
demonstrated program fidelity (including at least 90 days of consecutive negative toxicology 
screens for alcohol and illicit drug use), contingency is offered for up to six take-home doses, 
minimizing clinic visits to one per week. Though abstinence from alcohol and drugs is not 
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required for treatment, it is a requirement for take-home doses as it is seen as a way to prevent 
mixing methadone and other substances, which can lead to serious health consequences. Patients 
work with their counselors and treatment team to decrease or stop use of opiates and other 
substances. For clinical purposes, if patients miss doses for thirty consecutive days, they are 
considered to be no longer in treatment and require re-admission to the program. 
Participants 
Participants for this study (n=32) included UMDTC staff (n=8), peer recovery coaches 
(PRCs) working in the greater Baltimore community (n=4), and patients currently enrolled in 
MMT at UMDTC (n=20). Demographic and other descriptive characteristics of participants can 
be found in Table 1. A majority of participants, across patients, staff, and PRCs, identified as 
male and Black or African American. We recruited UMDTC staff (i.e. drug treatment 
counselors, case managers, nurses, and physicians) who were purposefully selected based on 
their roles in patient care and program administration. We also recruited PRCs, individuals with 
lived SU experience, who work in SU treatment in Baltimore City. PRCs were recruited through 
networking with a peer research collaborator and other community-based organizations in 
Baltimore City. As recommended in qualitative analysis, sample sizes are estimates of the 
number of individuals needed to reach theoretical saturation (Pope & Mays, 2006).  
Though qualitative work with staff and PRCs primarily included focus groups, 
participants were given the option of participating in focus groups or individual interviews to 
accommodate varying work schedules and personal preference. For the patient focus groups and 
semi-structured interviews, we recruited patients receiving MMT at UMDTC. In addition to 
recruitment with flyers and word of mouth, patients were referred by treatment program staff to 
purposefully sample patients who were both successfully engaged in treatment as well as 
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struggling with retention, allowing us to receive input from both perspectives. Staff utilized 
patient dosing records to identify patients who had missed at least five MMT doses in the past 
two weeks. Staff flagged those patients in the dosing system so they were given information 
about the study when they arrive for a dose on a day that a member of the research team was on-
site to conduct an interview. If interested in learning more about the research opportunity, those 
patients were introduced directly to a research team member and given the options of a same-day 
interview or scheduling an interview or focus group participation at a later date. 
All focus group and interview participants were provided gift card compensation in the 
amount of $25 for their time.  
All study procedures were reviewed and approved by the University of Maryland, 
College Park IRB with Interagency Agreement (IAA) approved by the University of Maryland, 
Baltimore.  
Procedures 
 We elected to conduct both focus groups and individual interviews to capture the patient, 
staff, and peer perspectives as fully as possible, recognizing that we may elicit different insights 
from these two qualitative methodologies. Focus groups allowed for shared ideas across the 
group and consensus on most common or pervasive barriers to successful treatment outcomes 
while individual interviews drew on the individual experience and allowed us to capture more 
specific examples of barrier co-occurrence and interactions. Focus groups included a maximum 
of six participants in each. Staff, peers, and patients chose to participate in a focus group or 
individual interview, but could not participate in both. Focus groups were separated such that 
patients only participated in focus groups with other patients. Staff and community peers 
participated in focus groups together.   
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We developed a semi-structured focus group and interview guides informed by 
syndemics theory to solicit feedback on syndemic factors influencing MMT outcomes in this 
population. Semi-structured guides were adapted in collaboration with local staff and 
stakeholders prior to finalizing and further adapted through an iterative process based on 
feedback from participants. Participants were asked to describe how patients define successful 
MMT outcomes. Therefore, conceptualization of successful outcomes and recovery were not 
restricted to treatment retention or MMT dosing-related measures. Open-ended questions 
inquired about observed barriers to positive/successful treatment outcomes and retention in 
MMT. Participants were asked if and how they understand these barriers to co-occur and affect 
one-another. The focus group guide utilized an interactive approach to allow participants to 
consider and write down their own ideas of most commonly experienced barriers to successful 
MMT outcomes. Written responses were collected by a focus group facilitator and presented 
back to the group to facilitate discussion. Focus group participants were then asked to vote on 
top three barriers. Group-determined top three barriers were used in the follow-up questions 
about interaction between co-occurring barriers (listing out and specifically inquiring about 
combinations of barriers). 
The individual interview guide similarly asked participants to identify three most 
common barriers to successful MMT outcomes and the interviewer used that information to ask 
questions about co-occurrence and how they may affect one another (as with focus groups, 
listing out and specifically inquiring about combinations of barriers).   
Analysis 
All recordings were transcribed and all transcriptions were double-checked for accuracy. 
Using thematic analysis, the coding team iteratively developed separate patient and staff/PRC 
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codebooks outlining themes, sub-themes, and definitions in the transcripts. These codebooks 
were modified as new concepts arose (Boyatzis, 1998). Using these established codebooks, two 
independent coders coded transcripts using Nvivo Version 12. The coders met weekly to discuss 
and resolve discrepancies in coding. A third person arbiter was involved in these meetings and 
resolution of coding discrepancies brought to these meetings were made by discussion and 
consensus. Transcripts were analyzed with thematic analysis (Braun & Clarke, 2006) informed 
by grounded theory (Glaser & Strauss, 1967) to deductively analyze themes from the interview 
guide while inductively identifying additional themes. The coders achieved high inter-coder 
reliability (=0.92) across larger study aims.  
Funding 
 This research was supported by a University of Maryland Dean’s Research Initiative 
grant awarded to Mary Kleinman. The parent award for this study was funded through an NIH 
HEAL Initiative grant (R61AT010799; PI: Magidson).  
Results 
Intersecting themes emerged from the patient and staff/PRC interviews and focus groups, 
based on our two study aims: to define barriers to MMT retention and successful treatment 
outcomes, and to identify interactions between specified barriers and their effects on successful 
treatment outcomes. In development of the conceptual framework and organization of identified 
barriers, we drew upon the social-ecological framework, originally developed by Bronfenbrenner 
(1979) and more recently applied to illustrate the dimensionality of the opioid crisis (Bunting et 
al., 2018; Jalali et al., 2020) and other qualitative research describing syndemics that include 
substance use (Nydegger & Claborn, 2020). 
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Barriers to MMT Retention and Successful Treatment Outcomes 
 When asked about challenges to staying in MMT and achieving successful treatment 
outcomes, participants described a range of barriers that they have experienced themselves in 
treatment or that they have observed others experiencing. While participants described MMT as 
lifesaving and a crucial component of recovery from OUD, every participant (patients, PRCs, 
and staff) readily shared substantial challenges faced in realizing the full benefit of MMT, and 
how participants defined successful MMT outcomes varied, including retention in treatment, 
abstinence from substances, discontinuation of treatment, and improved social relationships. 
Representative quotes for each of the themes described below can be found in Table 2a. Barriers 
to successful MMT outcomes, with organization below informed by the social-ecological 
framework (Bronfenbrenner, 1979), include factors at the individual-level, interpersonal- or 
social-level, institutional- or structural-level, and community- or environmental-level. 
Individual-Level Barriers 
 Participants shared a number of barriers that can be grouped together at the individual 
level, including patients describing barriers they themselves experience, and staff/PRCs  
describing barriers that their patients experience at the individual-level. One staff participant 
described this idea broadly saying, of patients, “they look at outside things as holding them back 
when it’s actually them” (Staff Participant, FG1). More specific individual-level barriers 
included the themes of individual health (mental and physical), motivation for engagement in 
treatment/recovery, readiness for change, sense of self-worth, and responsibilities or demands on 
time, which are all elaborated upon below.  
 Mental and Physical Health. Patient participants explained that they miss doses or have 
trouble staying in recovery when they feel tired: “sometimes I get depressed and tired and I don't 
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come” (Patient Participant, 1032) or are experiencing poor physical health, especially chronic 
pain. Much of what was shared in this theme of individual barriers related to unaddressed or 
undermanaged mental health concerns. One patient explained his experience this way: “my 
brain, it’s just the way it works…I’ve ruined it and I’ll never fix it, which is pretty sad” (Patient 
Participant, 1035). This also reflects an individual sense of hopelessness and low self-worth.   
 Motivation and Readiness for Change. Participants shared ideas about individual 
readiness and motivation for change. One staff participant described low motivation as patients 
not making a commitment to themselves and looking outside themselves for reasons why 
treatment is not working (Staff Participant, FG1). Similarly, but from a slightly different 
perspective, patient participants explain the idea of readiness for change, including different 
levels of engagement with treatment until they felt like they were ready for recovery. Patient 
participants shared the experience of being in the MMT program to avoid withdrawal symptoms, 
but not yet being ready for recovery. One patient participant shared, “This the third time I've 
been on the methadone program. The first two I walked off, because I really wasn't ready” and 
went on to explain that people start MMT for different reasons (e.g. avoiding withdrawal, 
looking for help, or court ordered) and readiness for change is an individual experience (Patient 
Participant, 1029). 
 Responsibilities and Demands on Time. Another sub-theme that came up at the 
individual level was responsibilities and demands on time. This idea reflects individual priorities 
that patients need to attend to for themselves, like sleep, self-care, and self-improvement (as one 
participant described the challenge of prioritizing her education). With a slightly different 
perspective, another participant shared her experience of idle or unstructured time as her biggest 
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barrier to successful treatment outcomes. She explained that she needs productive activities in 
order to distract her from cravings and triggers that would make her think about using.  
I just need something to do with this time of mine, you know what I mean? I get so 
frustrated with that. I just need something to do to absorb my time. (Patient Participant, 
1030) 
Meaningful use of time was common across responses. However, the way that MMT and other 
treatment or recovery activities factor into structuring that time differed between participants. 
Interpersonal- and Social-Level Barriers  
Social Influences. Many participants described needing to change “people, places, and 
things” in recovery from OUD. When, for a variety of reasons, they are unable to change the 
people with whom they spend their time, proximity to other people who use substances presents 
substantial challenges to modifying their own substance use or maintaining abstinence from 
substances. As described by one participant, “because of the company that we keep, we don't 
know how to change our thinking to be really ready to get clean” (Patient Participant, 1029). In 
addition to other people using drugs, interpersonal conflict and dealing with “negativity” of 
others can be overwhelming and makes it difficult to focus on recovery (Patient Participant, 
FG3). While some participants described a social circle that influenced them to use, a lack of 
healthy social support was another component of how social influences affected substance use in 
this population. Participants shared that lack of social support in their recovery is a major barrier 
to successful outcomes. One patient focus group discussion emerged around the idea that a 
person cannot be successful in recovery by themselves, but many people on MMT do not have 
family or a reliable support system. 
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Connection with Care Providers. Another challenge described by some participants 
was lack of clear communication with MMT providers in a way that they felt like their goals 
were understood. One patient participant explained that it can be difficult to express needs 
related to dosing, especially when MMT dose and effectiveness may be affected by other 
medications, such as antiretroviral medication for HIV. He said that it is hard to get on the same 
page about trying to feel better. Another patient participant described her goal of tapering off of 
MMT and said that she did not feel like her counselor shared that goal. Both participants 
expressed frustration with communicating needs to multiple people and not feeling like they 
were understood. Furthermore, and supporting what these patient participants described, a staff 
participant explained their perception of patient non-compliance. That staff participant described 
the feeling that patients are willfully non-compliant with program policies and emphasized her 
belief in the importance of discipline and structure (Staff Participant, FG1) while patient 
participants expressed frustration with staff not understanding the challenges that they face, 
“they got to learn how to be more understanding” (Patient Participant, FG3).  
Responsibilities and Demands on Time. Similar to the individual-level barrier of 
responsibilities and demands on time, this theme came up at the interpersonal level as 
responsibilities to other people, especially with employment. Though participants often described 
responsibilities and work as positive aspects of recovery, they included it as a reason for 
struggling with treatment when work or family responsibilities conflict with treatment 
responsibilities (i.e. dosing and meetings with care providers). Specifically, participants shared 
how it is challenging to balance employment and other interpersonal responsibilities in the 
context of the restrictive schedule of MMT typically requiring structured, daily dosing six days 
per week and frequent toxicology testing for recent drug use.  
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Institutional or Structural-Level Barriers  
The institutional and structural barriers that emerged, including coordination of care, 
program policies and schedule, unstable housing, and transportation, applied to both the 
treatment program at which the study took place as well as broader institutions, such as public 
services and other recovery programs. 
Coordination of Care. Participants described both the importance of coordinated, 
integrated services that support retention in MMT and address other health and mental health 
outcomes, yet also the institutional limitations in coordination of these services. The types of 
services mentioned included health care, including mental health care, and social services such 
as housing and financial assistance. Of particular concern among participants was coordination 
of mental health services with MMT. One patient participant mentioned difficulty finding a new 
doctor and a new therapist and said that this got in the way of focusing on recovery and MMT 
attendance. Another participant, when describing services available at the treatment center, said 
“one social worker, and she can’t see everybody, right? She can only do so much” (Patient 
Participant, 1030). A staff member also shared his experience that it is not enough to give 
patients information about available resources, they need to actually help connect them; but 
frequently counselors do not have the capacity to make those connections. That staff participant 
said “the most challenging part of it is where you’re unable to get everything that they need in 
one place” (Staff Participant, FG2). 
 Program Policies and Schedule. Multiple participants also brought up MMT program 
policies as barriers. Patient participants explained that assigned dosing times made them feel 
restricted as did unexpected program requirements when they arrived for dosing. One participant 
explained: 
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It seems like every week, there's something that's like holding that stops me. Because 
sometimes I mean, I have to get to work, and I go up to the window and they're like, ‘Oh, 
well, you gotta go see this person or this person, or this person.’ You know? (Patient 
Participant, 1038).  
The same participant described frustration with the policy of needing to have a job in order to 
qualify for early dosing since his job is “not on the books” but requires him to start work early. 
 Unstable Housing. Participants described challenges associated with other institutions 
and programs from which they receive services. The most commonly cited structural barrier was 
housing services. Several patient participants described their experience with applying for 
housing assistance and being on the waitlist. One participant said of her experience: 
I've been to housing around the corner from here and filled out an application and they 
said, only thing the lady said to me was ‘see you in seven years.’ (Patient Participant, 
1029) 
Another participant living in transitional housing for people in recovery said that she “plans [her] 
life around the program” because she recognized the importance of stable housing. However, 
meeting times and other requirements of the transitional housing program made it difficult for 
her to move forward with job opportunities and other things that she described as important to 
her independence and growth. Unstable housing and homelessness were the most frequently 
mentioned challenges in MMT, described as making it difficult to focus on recovery. All but two 
participants (across patients, staff, and PRCs) brought up housing as a “top three” barrier to 
successful treatment outcomes. 
Transportation. Unstable housing as well as where someone lives can impact 
engagement with MMT through challenges with transportation. One participant explained:  
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I've figured the buses out and everything, but it's still not driving. When scheduling is 
hard as it is already, not having a vehicle makes it even harder (Patient Participant 1036) 
Other patient participants echoed this difficulty with relying on buses both due to financial strain 
and the time that it takes to travel to the treatment program for daily dosing. 
Community or Environmental-Level Barriers 
 Community Violence. Participants shared the idea of community violence and concern 
about safety as a barrier to treatment. “You have some of those areas where there's [treatment] 
programs that you just don't want to be” (Patient Participant, 1016) and participants shared that 
they do not feel comfortable being in or traveling through some areas where there is a lot of 
violence.  
Environmental Triggers for SU. Similarly, some areas or environments were described 
by participants as triggering cravings. One patient participant shared that he tried to avoid these 
environmental triggers by staying at the MMT program for as long as he can, until they close, 
and then he said, “I go home, you don’t see me. I don’t come out for nothing” (Patient 
Participant, FG4).  
Homelessness. Additionally, as indicated above, homelessness is recognized as a major 
problem in the community served by this drug treatment center, and lack of affordable housing 
options can be considered a structural/institutional barrier as well as an environmental barrier. 
Housing, at the institutional-level was described as a systems barrier such that people are not 
able to access necessary housing resources as a result of bureaucracy. As a result, the 
environmental-level barrier of homelessness exists and affects the community such that “90% of 
everybody that’s still on drugs is homeless” (PRC participant, FG2).  
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Cross-Cutting Barrier: Stigma 
Another important barrier to successful treatment that cut across all of the levels 
described above was stigma. Specifically, participants shared how stigma affects OUD treatment 
both as stigma that medical providers demonstrate towards people who use drugs as well as 
stigma that patients perceive around use of MMT. Participants explained how medical providers 
demonstrate distrust of people who use drugs. One participant, in describing his experience 
trying to establish a pain management plan after surgery, said: 
Now, if doctors see that you’re on methadone in any way, you’re automatically judged and 
it should not be like that. (Patient Participant, FG3) 
Descriptions of stigma around MMT ranged from stigmatizing remarks by City officials and 
authority figures to family members believing that being on MMT means someone is still getting 
high. Participants explained that a common image of people on MMT is nodding off and not able 
to function and that this idea has been perpetuated at a high level such that the stereotype applies 
to the entire community and people refer to Baltimore as “the city that nods” (PRC Participant, 
FG3). 
Interrelationships Between Barriers 
 As described in the methods section, questions about interaction between barriers (or 
syndemic relationships) were solicited by interviewers using specific questions about what it is 
like to experience all different combinations of stated barriers together. In response to these 
questions about how the above described barriers may affect one another, a series of themes were 
identified that outlined interrelationships. Figure 1 provides a visual depiction of the 
relationships between barriers, with some acting in a linear manner and others reflecting a 
multiplicative effect. Table 2b includes representative quotes for each of the identified 
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relationships. Although participants shared many thoughts on co-occurring barriers, the 
relationships between barriers reflected here are limited to those for which participants specified 
a worsening effect rather than just co-occurrence, as this was the aim of questions referring to 
syndemic relationships and in-line with current syndemics theory (Singer et al., 2020).  
 At a broad level, when asked about the co-occurrence of barriers, participants shared their 
belief that certain barriers have a multiplicative effect on one another. One participant, when 
talking about her challenges with getting stable housing said: 
Then you have all the other issues in between just set it off like it's a bomb and it just 
goes off and it just branches out, you know what I mean, in different places. It branches 
out in different places. (Patient Participant, 1029) 
Another participant shared her thoughts on unreliable transportation and responsibilities and 
demands on her time: “Oh, they just make it worse. Just make it ten times worse” (Patient 
Participant, 1030). 
 Table 2b provides representative quotes for eight distinct interrelationships between 
barriers that were described by participants, and these are summarized more generally below.   
  Unstable Housing and Mental Health. The interaction between unstable housing and 
mental health and motivation reflects a relationship in which the barrier of unstable housing 
worsened the effect of mental health and motivation. Participants described the mental strain and 
demoralization of applying for and not being able to secure stable housing. One participant 
shared that her housing situation led to major depression saying about the housing application 
process “it just sent me over the edge” (Patient Participant, 1030).   
 Transportation Barriers, Physical Health, Demands on Time. Distance from 
treatment (and related difficulty with transportation) was described as interacting with poor 
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physical health or pain and responsibilities and demands on time such that distance from the 
treatment program worsened the effect of each of those barriers on missed MMT doses. The need 
to travel far or use unreliable transportation to get to the treatment program worsened the effect 
that poor physical health and pain have on attending MMT dosing visits. Distance and difficulty 
with transportation also exacerbated the impact other responsibilities and demands on time had 
on dosing visit attendance as do program policies and schedule.   
Let's say they've got an appointment, my dose is at eight o'clock. But I have an 
appointment at eight o'clock that I can't miss. I go to my appointment of course, that 
means I'm not going to be able to get dosed until later in the day, again, you start feeling 
bad, things start going up in your head, thinking about going and getting something out 
there to make you feel better. (Patient Participant, 1039) 
Another participant remarked that “if I had transportation, I could definitely get here and get out 
of there quickly and be at work and not have any issues with that” (Patient Participant, 1036). 
 Community Violence and Distance from Treatment. Community violence and concern 
about safety also had a syndemic effect on the direct relationship between distance from 
treatment/transportation and missed MMT doses such that participants reported avoiding 
neighborhoods or areas that are also necessary to get to the treatment center.  
 Program Policies and Responsibilities/Demands on Time. Further discussion about 
program policies and the interaction with other demands included the following statement from a 
patient. 
If you know it's already a problem trying to get here and now you have to get here at a 
certain time, what if that messes with your schedule? That was a big issue. So, I mean, 
that was the only thing I can really come up with that was an issue… I've seen people 
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move you know, because of that schedule issue. Just say ‘screw it,’ not even, you know, 
end up leaving and they go get high. (Patient Participant 1038) 
This experience reflected the effect that program policies, in this case dosing schedule, had on 
the challenges of other demands on time. The larger context of this participant’s quote was 
discussion about employment responsibilities and trying to keep a job.  
 Stigma and Physical/Mental Health. Regarding stigma that medical providers have 
around SUD and MOUD, participants shared experiences with or beliefs about not being able to 
get medication for debilitating pain due to stereotypes of people who use drugs. Since pain is a 
barrier to attending MMT dosing appointments, stigma and inadequate medical care have a 
worsening effect. Also, participants described the effect that stigma around MOUD had on sense 
of self-worth and mental health such that “they always felt less than” (PRC Participant, FG2). 
This can have a compounding effect on low self-worth and pre-existing mental health conditions.     
Discussion 
 This study aimed to develop a preliminary conceptual model of barriers to successful 
MMT outcomes and the syndemic relationships between these barriers. To our knowledge, this is 
the first study to apply syndemics theory to understanding treatment outcomes for OUD. Based 
on qualitative feedback from patients, staff, and PRCs, we developed a preliminary conceptual 
model that describes syndemic relationships that impact poor MMT treatment outcomes. We 
utilized the social-ecological framework to organize the levels of barriers that emerged from 
participant responses (individual, social, institutional, and environmental). This approach 
allowed us to incorporate patient perspective and voice into how we understand the experience of 
barriers at these multiple levels. Patient, staff, and PRC participants had complementary 
responses across themes that reflected similar ideas in response to primary study aims. 
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The four levels of barriers that were identified in thematic analysis included distinct as 
well as cross-cutting and interacting factors. At the individual level, participants described 
barriers related to personal health and readiness for change. At the social level, they shared 
barriers experienced in the context of social circles that influence substance use as well as lack of 
social support. At the institutional level, barriers included housing as well as challenges with 
program policies and schedules, and at the environmental level, barriers included community 
violence and environmental triggers for substance use. Participant descriptions of the impact of 
stigma (related to SU and MMT) on treatment outcomes arose across all of the social-ecological 
framework levels. Importantly, stigma in the context of this analysis was focused on participant 
descriptions of how they recognized stigma existing and affecting treatment and recovery.  
Descriptions of barriers to successful MMT outcomes in this study align with previously 
published challenges associated with MOUD outcomes. Past studies have demonstrated the 
association of psychiatric comorbidity (Kidorf, 2018), homelessness (Lo et al., 2018), violent 
victimization (Lo et al., 2018), and stigma (related to MMT and/or substance use) (Tsai et al., 
2019; Woo et al., 2017) with poor MOUD outcomes and treatment discontinuation. The barriers 
described by participants in this study are consistent with what has been published in the past, 
both from qualitative and quantitative research. Furthermore, the social-ecological framework is 
well established for conceptual organization of factors associated with substance use morbidity, 
recovery, and treatment. A qualitative study looking at barriers to treatment for people with OUD 
recently released from prison used this framework to describe themes that came out of interviews 
with clinicians and, similar to our study, reported individual-level motivation, social circle that 
influences substance use, and over-stretched clinician capacity as examples of individual, social, 
and institutional barriers to treatment (Bunting et al., 2018). A unique aspect of the current study 
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is the focus on syndemics theory and the interaction between barriers across social-ecological 
levels.  
 We distinguished between syndemic relationships and other interrelationships of co-
occurring barriers in order to provide clarity in the definition of syndemics. Mere co-occurrence 
and clustering of disease and adversity does not meet criteria to be defined as a syndemic. 
Thought leaders on the topic of syndemics have described that the concept is not “synonym of 
comorbidity” (“Syndemics,” 2017) and must include a proposed mechanism by which the 
association occurs (Bhardwaj & Kohrt, 2020). Specifically, leaders in the field have critiqued 
how the concept of syndemics has been inappropriately applied to any clustering of social 
determinants of health and a “sum score” approach to analysis has proliferated a serious 
misunderstanding in the literature (Tsai, 2018). The sum score approach to analysis implies 
additive effects that would suggest very different intervention approaches compared to syndemic 
interactions that have a multiplicative effect. The current analysis identified co-occurrence of 
many barriers, and the conceptual model detailed in Figure 1 allows for the distinction between 
the different types of relationships between barriers (i.e., direct effect, interactive relationship). 
We differentiated between the sequential effect of unstable housing on social circle that 
influences substance use and other relationships between barriers that seem to interact 
differently. Thus, future research can test these relationships with intentionality and consider 
intervention options that most efficiently target the effect of unique relationships between 
barriers. Furthermore, the levels of barriers in this conceptual model are in-line with 
methodological recommendations for incorporation of ecological- and individual-level in 
development of multi-level models of syndemics (Tsai et al., 2017).  
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 Syndemic theory has recently received a lot of attention in scientific literature with a 
2017 Lancet series bringing together ideas about this framework as a means of understanding 
disease and health conditions in global populations (“Syndemics,” 2017). Qualitative research to 
inform mechanisms of syndemic relationships has been undertaken previously, especially in the 
context of HIV risk and treatment (Gagnon, 2018; Lyons et al., 2013; Quinn et al., 2018). 
However, qualitative research to inform syndemic factors affecting MMT treatment outcomes 
has not previously been undertaken but is crucial to allow for further meaningful research in this 
area, especially informing quantitative analyses. Conceptualization of syndemics in the context 
of OUD has been limited and has focused on the impact of OUD on other health outcomes, such 
as suicide (Fornili, 2018) and infectious diseases (Perlman & Jordan, 2018). Our study lays the 
groundwork for expansion of syndemics theory to better understand barriers of successful OUD 
treatment outcomes.  
The syndemics literature has been cited in recommendations for public health 
interventions (Hart & Horton, 2017; Willen et al., 2017). As described above, the way that we 
conceptualize syndemic interactions carries implications for most effective means of intervening 
on these factors. With the understanding of a multiplicative effect, an intervention targeting one 
factor would have a greater impact on treatment outcomes than would be expected if no 
interaction was present (Tsai, 2018). So, we can harness information gathered from syndemics 
research to promote efficiency in intervention decisions, which is especially important in low-
resource settings experiencing high disease burden (such as economically disadvantaged areas of 
Baltimore City, where this study took place, which are experiencing high mortality in the opioid 
epidemic).  
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In recent research, syndemics theory has been used to build transdiagnostic treatment 
protocols (Safren et al., 2020). Safren and colleagues sought to develop a unified protocol to 
address mental health and related psychosocial syndemic factors in people living with 
uncontrolled HIV in Miami, FL. They initially intended to implement a unified protocol with 
standard content for all patients (based on CBT for adherence and depression), but found that 
specific barriers to treatment and complex life circumstances described by individual patients 
were best addressed through a module-based design where content was selected “based on life 
circumstances and particular set of mental health and social-structural comorbidities” (Safren et 
al., 2020, p. 3275). Implementation of such a module-based design for people facing challenges 
in MOUD can be informed by the conceptual model presented in the current study to help select 
the most efficient strategies to target high-impact barriers (those that have a synergistic effect on 
other barriers). Safren and colleagues also describe the importance of integrated case 
management and linkage to wraparound services that holistically address complex social-
structural barriers faced by patients in treatment for HIV. Similar recommendations were made 
by participants in a qualitative study informing implementation of a PRC-delivered intervention 
(based on Behavioral Activation for substance use) to support linkage to and retention in 
treatment for SUD (Satinsky et al., 2020). Our research, and future studies elaborating on 
syndemic barriers to MOUD, should be used to consider similar intervention approaches for 
people facing challenges in treatment.  
Limitations 
Findings must be considered in the context of methodological limitations that should be 
addressed in future research expanding on this topic. First, as a study employing only qualitative 
methodology, the findings are not intended to be generalizable. Second, though we employed 
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procedures to reach a diverse sample of patient participants (both consistently and inconsistently 
attending dosing visits), inclusion criteria necessitated that patient participants be actively 
enrolled in the MMT program. Therefore, we were unable to get the perspective of patients who 
discontinued MMT and have not returned to treatment. Participant responses were also limited 
by narrow staff representation with only one participant representing medical staff in the MMT 
program. We also recognize the limitations to generalizability given this study recruited patients 
and staff from just one treatment program and one MOUD modality (MMT versus other options 
such as buprenorphine or naltrexone). Third, as a result of the scope of the current study, barriers 
were classified into relatively broad categories, such as mental health and physical health. 
Though this approach is common in the literature, recent recommendations promote a more 
granular approach that allows for identification of more specific pathways and processes of 
interaction (Bhardwaj & Kohrt, 2020). Finally, although we use language describing syndemic 
factors as affecting treatment outcomes based on participant responses regarding their 
perceptions of these factors, we recognize that we are not able to make substantiated claims 
about causality using a cross-sectional, qualitative design.  
Design Considerations 
Several study design considerations are important to note. First, an important aspect of 
how the interview and focus group guides solicited feedback from participants is the way that 
successful treatment outcomes were defined. Participants were asked to share their own, personal 
definitions of successful MMT outcomes. Therefore, there was no pre-set, common definition of 
successful treatment nor consensus on how ongoing substance use fits into that definition. Thus, 
substance use was included as a mediator between other barriers and successful treatment 
outcomes in the conceptual model. However, depending on individual participant beliefs, 
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substance use may also be conceptualized as an independent barrier affecting treatment outcomes 
or a component of the definition of poor treatment outcomes. Additionally, this qualitative 
research was designed to inform quantitative assessment of the syndemic barriers identified. 
Quantitative data collection progress was delayed by the COVID-19 pandemic, however is in 
progress and will be an important next step following from this research.  
Several program policy changes  took place at the treatment center between starting this 
study and completion of the last interview. Early study participants described challenges 
associated with assigned dosing times, especially interfering with other responsibilities and 
demands on time, but the program eliminated dosing times before the final patient interview and 
now allow patients to attend dosing visits anytime between 7:00 am and 1:30 pm (though earlier 
time is still reserved for patients who need early dosing and have documented jobs). Although it 
was not a study aim to get feedback from participants on this particular change, one patient 
participant shared that it was a good thing that they “finally got rid of [dosing times]” (Patient 
Participant, 1036).  
Although the qualitative data collection was not directly impacted by the global COVID-
19 pandemic, it is important to acknowledge several programmatic changes that have resulted 
from COVID-19.  The pandemic and lockdown/social distancing response has affected people 
living with OUD broadly, likely exacerbating some barriers to treatment described in this study. 
However, the pandemic has had a unique impact on people receiving MMT as a result of 
national regulatory modifications to policies around take-home dosing and frequency of in-
person visits (SAMHSA, 2020). Some people have been advocating for loosening MMT dosing 
restrictions and increasing access to take-home dosing before and outside the context of the viral 
pandemic (Green et al., 2020; Greenblatt et al., 2020). Research is underway to investigate the 
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impact of these treatment changes, both positive and negative, and understand how they may 
have affected the interrelationships of barriers identified pre-pandemic (R61AT010799-01S1; PI: 
Magidson). The proposed conceptual model will be an important guide as we consider the 
unique vulnerabilities individuals with OUD face in achieving successful OUD treatment 
outcomes during COVID-19.  
Conclusions and Future Directions 
This qualitative study, including perspectives from patients and staff of an MMT program 
as well as PRCs who work in diverse drug treatment settings, is the first to apply syndemics 
theory to understanding OUD treatment outcomes. As syndemics theory is expanding from its 
original conceptualization in HIV outcomes to application in other public health contexts, the use 
of this theory to establish a framework of relationships between barriers to successful MMT 
outcomes has strong public health implication. Enormous morbidity and mortality in the opioid 
epidemic must be targeted with intentional interventions that address barriers and their 
interactions across levels of the social-ecological framework. The conceptual framework of 
syndemic barriers to successful OUD treatment outcomes can provide a basis for future study 
and intervention development to enhance outcomes of MMT for people living with complex 
psychosocial, interpersonal, and structural challenges. We hope this proposed conceptual model 
will be used to inform future research to further investigate and quantify these syndemic barriers 
in relation to MOUD outcomes (MMT and more broadly), as well as inform transdiagnostic 
behavioral interventions based on syndemics theory that address individuals’ barriers at multiple 
levels.   




Baltimore City Health Department. (2018). Baltimore City’s Response to the Opioid Epidemic. 
https://health.baltimorecity.gov/opioid-overdose/baltimore-city-overdose-prevention-and-
response-information 
Bhardwaj, A., & Kohrt, B. A. (2020). Syndemics of HIV with mental illness and other 
noncommunicable diseases: A research agenda to address the gap between syndemic 
theory and current research practice. Current Opinion in HIV and AIDS, 15(4), 226–231. 
https://doi.org/10.1097/COH.0000000000000627 
Blashill, A. J., Bedoya, C. A., Mayer, K. H., O’Cleirigh, C., Pinkston, M. M., Remmert, J. E., 
Mimiaga, M. J., & Safren, S. A. (2015). Psychosocial syndemics are additively associated 
with worse ART adherence in HIV-infected individuals. AIDS and Behavior, 19(6), 981–
986. https://doi.org/10.1007/s10461-014-0925-6 
Boyatzis, R. E. (1998). Transforming Qualitative Information: Thematic Analysis and Code 
Development (1 edition). SAGE Publications, Inc. 
Braun, V., & Clarke, V. (2006). Using thematic analysis in psychology. Qualitative Research in 
Psychology, 3(2), 77–101. https://doi.org/10.1191/1478088706qp063oa 
Bronfenbrenner, U. (1979). The Ecology of Human Development: Experiments by Nature and 
Design. Harvard University Press. 
Bunting, A. M., Oser, C. B., Staton, M., Eddens, K. S., & Knudsen, H. (2018). Clinician 
identified barriers to treatment for individuals in Appalachia with opioid use disorder 
following release from prison: A social ecological approach. Addiction Science & 
Clinical Practice, 13. https://doi.org/10.1186/s13722-018-0124-2 
PSYCHOSOCIAL SYNDEMICS AND MOUD OUTCOMES 
 
31 
Carpentier, P. J., Krabbe, P. F. M., van Gogh, M. T., Knapen, L. J. M., Buitelaar, J. K., & de 
Jong, C. A. J. (2009). Psychiatric comorbidity reduces quality of life in chronic 
methadone maintained patients. American Journal on Addictions, 18(6), 470–480. 
Centers for Disease Control and Prevention (CDC). (2018). National drug overdose deaths 
involving any opioid. National Center for Health Statistics, Multiple Causes of Death 
1999-2017 on CDC WONDER Online Database. 
Engstrom, M., El-Bassel, N., & Gilbert, L. (2012). Childhood sexual abuse characteristics, 
intimate partner violence exposure, and psychological distress among women in 
methadone treatment. Journal of Substance Abuse Treatment, 43(3), 366–376. 
https://doi.org/10.1016/j.jsat.2012.01.005 
Exec. Order No. 01.01.2017.02. (2017). Executive Order Regarding the Heroin, Opioid, and 
Fentanyl Overdose Crisis Declaration of Emergency. 
Exec. Order No. 01.01.2019.02. (2019). Commission to Study Mental and Behavioral Health in 
Maryland. 
Fornili, K. (2018). The opioid crisis, suicides, and related conditions: Multiple clustered 
syndemics, not singular epidemics. Journal of Addictions Nursing, 29(3), 214–220. 
https://doi.org/10.1097/JAN.0000000000000240 
Gagnon, M. (2018). “There is a chain of connections”: Using syndemics theory to understand 
HIV treatment side effects. AIDS Care, 30(7), 910–913. 
https://doi.org/10.1080/09540121.2018.1450478 
Glaser, B. G., & Strauss, A. L. (1967). The Discovery of Grounded Theory: Strategies for 
Qualitative Research. Aldine. 
PSYCHOSOCIAL SYNDEMICS AND MOUD OUTCOMES 
 
32 
Green, T. C., Bratberg, J., & Finnell, D. S. (2020). Opioid use disorder and the COVID 19 
pandemic: A call to sustain regulatory easements and further expand access to treatment. 
Substance Abuse, 41(2), 147–149. https://doi.org/10.1080/08897077.2020.1752351 
Greenblatt, A. D., Magidson, J. F., Belcher, A. M., Ghandi, D., & Weintraub, E. (2020). Overdue 
for an overhaul: How opioid treatment programs can learn from COVID-19. Mayo Clinic 
Proceedings. https://doi.org/10.1016/j.mayocp.2020.08.011 
Harkness, A., Bainter, S. A., O’Cleirigh, C., Mendez, N. A., Mayer, K. H., & Safren, S. A. 
(2018). Longitudinal effects of syndemics on ART non-adherence among sexual minority 
men. AIDS and Behavior, 22(8), 2564–2574. https://doi.org/10.1007/s10461-018-2180-8 
Hart, L., & Horton, R. (2017). Syndemics: Committing to a healthier future. The Lancet, 
389(10072), 888–889. https://doi.org/10.1016/S0140-6736(17)30599-8 
Jalali, M. S., Botticelli, M., Hwang, R. C., Koh, H. K., & McHugh, R. K. (2020). The opioid 
crisis: A contextual, social-ecological framework. Health Research Policy and Systems, 
18(1), 87. https://doi.org/10.1186/s12961-020-00596-8 
Joseph, H., Stancliff, S., & Langrod, J. (2000). Methadone maintenance treatment (MMT): A 
review of historical and clinical issues. The Mount Sinai Journal of Medicine, New York, 
67(5–6), 347–364. 
Kaiser Family Foundation. (2020, February). Opioid Overdose Death Rates and All Drug 
Overdose Death Rates per 100,000 Population (Age-Adjusted). The Henry J. Kaiser 
Family Foundation. https://www.kff.org/other/state-indicator/opioid-overdose-death-
rates/ 
Kidorf, M. (2018). Psychiatric and substance use comorbidity in treatment-seeking injection 
opioid users referred from syringe exchange. Journal of Dual Diagnosis, 1–8. 
PSYCHOSOCIAL SYNDEMICS AND MOUD OUTCOMES 
 
33 
Lo, A., Kerr, T., Hayashi, K., Milloy, M.-J., Nosova, E., Liu, Y., & Fairbairn, N. (2018). Factors 
associated with methadone maintenance therapy discontinuation among people who 
inject drugs. Journal of Substance Abuse Treatment, 94, 41–46. 
https://doi.org/10.1016/j.jsat.2018.08.009 
Lyons, T., Johnson, A. K., & Garofalo, R. (2013). “What could have been different”: A 
qualitative study of syndemic theory and HIV prevention among young men who have 
sex with men. Journal of HIV/AIDS & Social Services, 12(3–4). 
https://doi.org/10.1080/15381501.2013.816211 
National Academies of Sciences, Engineering, and Medicine. (2018). Medication-Assisted 
Treatment for Opioid Use Disorder: Proceedings of a Workshop—in Brief. National 
Academies Press (US). http://www.ncbi.nlm.nih.gov/books/NBK534504/ 
National Institutes of Health (NIH). (2018). Principles of Drug Addiction Treatment: A 
Research-Based Guide (Third Edition). National Institute on Drug Abuse. 
https://www.drugabuse.gov/publications/principles-drug-addiction-treatment-research-
based-guide-third-edition/principles-effective-treatment 
Nydegger, L. A., & Claborn, K. R. (2020). Exploring patterns of substance use among highly 
vulnerable Black women at-risk for HIV through a syndemics framework: A qualitative 
study. PLOS ONE, 15(7), e0236247. https://doi.org/10.1371/journal.pone.0236247 
Perlman, D. C., & Jordan, A. E. (2018). The syndemic of opioid misuse, overdose, HCV, and 
HIV: Structural-level causes and interventions. Current HIV/AIDS Reports, 15(2), 96–
112. https://doi.org/10.1007/s11904-018-0390-3 
Pope, C., & Mays, N. (Eds.). (2006). Qualitative Research in Health Care (3 edition). BMJ 
Books. 
PSYCHOSOCIAL SYNDEMICS AND MOUD OUTCOMES 
 
34 
Quinn, K. G., Reed, S. J., Dickson-Gomez, J., & Kelly, J. A. (2018). An exploration of syndemic 
factors that influence engagement in HIV care among black men. Qualitative Health 
Research, 28(7), 1077–1087. https://doi.org/10.1177/1049732318759529 
Reisinger, H. S., Schwartz, R. P., Mitchell, S. G., Peterson, J. A., Kelly, S. M., O’Grady, K. E., 
Marrari, E. A., Brown, B. S., & Agar, M. H. (2009). Premature discharge from 
methadone treatment. Journal of Psychoactive Drugs, 41(3), 285–296. 
Safren, S. A., Harkness, A., Lee, J. S., Rogers, B. G., Mendez, N. A., Magidson, J. F., Blashill, 
A. J., Bainter, S., Rodriguez, A., & Ironson, G. (2020). Addressing syndemics and self-
care in individuals with uncontrolled HIV: An open trial of a transdiagnostic treatment. 
AIDS and Behavior, 24(11), 3264–3278. https://doi.org/10.1007/s10461-020-02900-7 
Satinsky, E. N., Doran, K., Felton, J. W., Kleinman, M., Dean, D., & Magidson, J. F. (2020). 
Adapting a peer recovery coach-delivered behavioral activation intervention for 
problematic substance use in a medically underserved community in Baltimore City. PloS 
One, 15(1), e0228084. https://doi.org/10.1371/journal.pone.0228084 
Singer, M. (1996). A dose of drugs, a touch of violence, a case of AIDS: Conceptualizaing the 
SAVA syndemic. Free Inquiry in Creative Sociology, 24(2), 99–110. 
Singer, M. (2009). Introduction to syndemics: A critical systems approach to public and 
community health (1st ed). Jossey-Bass. 
https://catalyst.library.jhu.edu/catalog/bib_3487422 
Singer, M., Bulled, N., & Ostrach, B. (2020). Whither syndemics?: Trends in syndemics 
research, a review 2015–2019. Global Public Health, 15(7), 943–955. 
https://doi.org/10.1080/17441692.2020.1724317 
PSYCHOSOCIAL SYNDEMICS AND MOUD OUTCOMES 
 
35 
Sordo, L., Barrio, G., Bravo, M. J., Indave, B. I., Degenhardt, L., Wiessing, L., Ferri, M., & 
Pastor-Barriuso, R. (2017). Mortality risk during and after opioid substitution treatment: 
Systematic review and meta-analysis of cohort studies. BMJ, 357, j1550. 
https://doi.org/10.1136/bmj.j1550 
Stall, R., Mills, T. C., Williamson, J., Hart, T., Greenwood, G., Paul, J., Pollack, L., Binson, D., 
Osmond, D., & Catania, J. A. (2003). Association of co-occurring psychosocial health 
problems and increased vulnerability to HIV/AIDS among urban men who have sex with 
men. American Journal of Public Health, 93(6), 939–942. 
Substance Abuse and Mental Health Services Administration (SAMHSA). (2020). Opioid 
Treatment Program (OTP) Guidance. www.samhsa.gov/ sites/default/files/otp-guidance-
20200316.pdf 
Syndemics: Health in context. (2017). The Lancet, 389(10072), 881. 
https://doi.org/10.1016/S0140-6736(17)30640-2 
Tsai, A. C. (2018). Syndemics: A theory in search of data or data in search of a theory? Social 
Science & Medicine, 206, 117–122. https://doi.org/10.1016/j.socscimed.2018.03.040 
Tsai, A. C., Kiang, M. V., Barnett, M. L., Beletsky, L., Keyes, K. M., McGinty, E. E., Smith, L. 
R., Strathdee, S. A., Wakeman, S. E., & Venkataramani, A. S. (2019). Stigma as a 
fundamental hindrance to the United States opioid overdose crisis response. PLOS 
Medicine, 16(11), e1002969. https://doi.org/10.1371/journal.pmed.1002969 
Tsai, A. C., Mendenhall, E., Trostle, J. A., & Kawachi, I. (2017). Co-occurring epidemics, 
syndemics, and population health. The Lancet, 389(10072), 978–982. 
https://doi.org/10.1016/S0140-6736(17)30403-8 
PSYCHOSOCIAL SYNDEMICS AND MOUD OUTCOMES 
 
36 
US Department of Health & Human Services. (2017). HHS Acting Secretary Declares Public 
Health Emergency to Address National Opioid Crisis [Press release]. 
https://www.hhs.gov/about/news/2017/10/26/hhs-acting-secretary-declares-public-health-
emergency-address-national-opioid-crisis.html 
Willen, S. S., Knipper, M., Abadía-Barrero, C. E., & Davidovitch, N. (2017). Syndemic 
vulnerability and the right to health—The Lancet. The Lancet, 389(10072), 964–977. 
Wilson, P. A., Nanin, J., Amesty, S., Wallace, S., Cherenack, E. M., & Fullilove, R. (2014). 
Using syndemic theory to understand vulnerability to HIV infection among black and 
latino men in New York City. Journal of Urban Health : Bulletin of the New York 
Academy of Medicine, 91(5), 983–998. https://doi.org/10.1007/s11524-014-9895-2 
Woo, J., Bhalerao, A., Bawor, M., Bhatt, M., Dennis, B., Mouravska, N., Zielinski, L., & 
Samaan, Z. (2017). “Don’t judge a book by its cover”: A qualitative study of methadone 
patients’ experiences of stigma. Substance Abuse: Research and Treatment, 11. 
https://doi.org/10.1177/1178221816685087 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
